Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Linda Pearson who wrote (123)	12/1/1997 9:58:00 PM
From: George Dawson	Respond to of 942

Linda, This was a different excerpt from the article: "It strengthened its recommendations about the drug, known generically as troglitazone, after reports that some people on the drug had suffered liver failure and three had died." It may be an idiosyncratic reaction, but the overall impression is that there more concern and uncertainty. As an example, there are drugs taken by 2 - 3 x as many people for more years, but cause this many deaths from liver failure. I think it also explains why WLA is saying that the risk is much less than the risk from diabetes, while the drug as withdrawn temporarily in the U.K.

To: Linda Pearson who wrote (123)	12/2/1997 12:10:00 AM
From: Zoltan!	Read Replies (1) \| Respond to of 942

>>Need I say more Yes, because those are old figures. In the last month they have increased by over 300%. Figures are still small but the jump is alarming. The FDA says it has received about 150 reports of adverse events, a substantial increase from the 35 reports it had received through late October that led to the initial warning to doctors. interactive.wsj.com Regards